Orchid-Bio Pharma Ltd (wholly owned subsidiary of Orchid Pharma) has entered into an MoU with overseas technology provider for in-licensing of ‘7ACA’, a technology. Orchid also has obtained a Production Linked Incentive for manufacturing this product.
7-ACA (7-aminocephalosporanic acid) is the core chemical structure for the synthesis of C antibiotics and intermediates.
This will help reduce the dependence on imports for this product and enhance their backward integration.